These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
126 related articles for article (PubMed ID: 11774586)
1. Presence and functions of immune components in the tumor microenvironment. Witz IP Adv Exp Med Biol; 2001; 495():317-24. PubMed ID: 11774586 [No Abstract] [Full Text] [Related]
3. Booming cancer immunotherapy fighting tumors. Li D; Wang W Sci China Life Sci; 2017 Dec; 60(12):1445-1449. PubMed ID: 29170888 [No Abstract] [Full Text] [Related]
5. Identification of the genes encoding cancer antigens: implications for cancer immunotherapy. Rosenberg SA; Kawakami Y; Robbins PF; Wang R Adv Cancer Res; 1996; 70():145-77. PubMed ID: 8902056 [No Abstract] [Full Text] [Related]
6. The HIF-1α hypoxia response in tumor-infiltrating T lymphocytes induces functional CD137 (4-1BB) for immunotherapy. Palazón A; Martínez-Forero I; Teijeira A; Morales-Kastresana A; Alfaro C; Sanmamed MF; Perez-Gracia JL; Peñuelas I; Hervás-Stubbs S; Rouzaut A; de Landázuri MO; Jure-Kunkel M; Aragonés J; Melero I Cancer Discov; 2012 Jul; 2(7):608-23. PubMed ID: 22719018 [TBL] [Abstract][Full Text] [Related]
7. Mechanisms of tumor escape in the context of the T-cell-inflamed and the non-T-cell-inflamed tumor microenvironment. Spranger S Int Immunol; 2016 Aug; 28(8):383-91. PubMed ID: 26989092 [TBL] [Abstract][Full Text] [Related]
9. CANCER IMMUNOLOGY. The "cancer immunogram". Blank CU; Haanen JB; Ribas A; Schumacher TN Science; 2016 May; 352(6286):658-60. PubMed ID: 27151852 [No Abstract] [Full Text] [Related]
10. Apoptosis of tumor-infiltrating T lymphocytes: a new immune checkpoint mechanism. Zhu J; Petit PF; Van den Eynde BJ Cancer Immunol Immunother; 2019 May; 68(5):835-847. PubMed ID: 30406374 [TBL] [Abstract][Full Text] [Related]
11. Adoptive cellular immunotherapy of cancer. Winter H; Fox BA Curr Opin Mol Ther; 1999 Feb; 1(1):89-97. PubMed ID: 11249690 [No Abstract] [Full Text] [Related]
13. Characterizing parathyroid carcinomas and atypical neoplasms based on the expression of programmed death-ligand 1 expression and the presence of tumor-infiltrating lymphocytes and macrophages. Silva-Figueroa A; Villalobos P; Williams MD; Bassett RL; Clarke CN; Lee JE; Busaidy NL; Perrier ND Surgery; 2018 Nov; 164(5):960-964. PubMed ID: 30033186 [TBL] [Abstract][Full Text] [Related]
14. Are tumor-infiltrating lymphocytes protagonists or background actors in patient selection for cancer immunotherapy? Zito Marino F; Ascierto PA; Rossi G; Staibano S; Montella M; Russo D; Alfano R; Morabito A; Botti G; Franco R Expert Opin Biol Ther; 2017 Jun; 17(6):735-746. PubMed ID: 28318336 [TBL] [Abstract][Full Text] [Related]
15. Tumor microenvironment and lymphocyte infiltration. Rahir G; Moser M Cancer Immunol Immunother; 2012 Jun; 61(6):751-9. PubMed ID: 22488275 [TBL] [Abstract][Full Text] [Related]
17. The biology of cancer gene therapy. Whartenby KA; Abboud CN; Marrogi AJ; Ramesh R; Freeman SM Lab Invest; 1995 Feb; 72(2):131-45. PubMed ID: 7853848 [No Abstract] [Full Text] [Related]
18. Classification of Advanced Human Cancers Based on Tumor Immunity in the MicroEnvironment (TIME) for Cancer Immunotherapy. Zhang Y; Chen L JAMA Oncol; 2016 Nov; 2(11):1403-1404. PubMed ID: 27490017 [No Abstract] [Full Text] [Related]
20. Regulatory T cells in cancer; can they be controlled? Adeegbe DO; Nishikawa H Immunotherapy; 2015; 7(8):843-6. PubMed ID: 26316166 [No Abstract] [Full Text] [Related] [Next] [New Search]